Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST.

Kairemo K, Rohren EM, Anderson PM, Ravizzini G, Rao A, Macapinlac HA, Subbiah V.

ESMO Open. 2019 Feb 28;4(1):e000439. doi: 10.1136/esmoopen-2018-000439. eCollection 2019.

2.

An International Survey of PET/CT Clinical Reporting.

Zukotynski KA, Niederkohr RD, Greenspan BS, Prior JO, Schöder H, Seltzer MA, Rohren EM, Yoo DC.

J Nucl Med. 2019 Apr;60(4):478-479. doi: 10.2967/jnumed.118.223073. Epub 2019 Mar 15. No abstract available.

PMID:
30877176
3.

Is interim 18F-fluoride PET/CT a predictor of outcomes after radium-223 therapy?

Etchebehere E, Brito AE, Kairemo K, Rohren E, Araujo J, Macapinlac H.

Radiol Bras. 2019 Jan-Feb;52(1):33-40. doi: 10.1590/0100-3984.2017.0178.

4.

Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial.

Subbiah V, Anderson PM, Kairemo K, Hess K, Huh WW, Ravi V, Daw NC, Somaiah N, Ludwig JA, Benjamin RS, Chawla S, Hong DS, Meric-Bernstam F, Ravizzini G, Kleinerman E, Macapinlac H, Rohren E.

Clin Cancer Res. 2019 Jul 1;25(13):3802-3810. doi: 10.1158/1078-0432.CCR-18-3964. Epub 2019 Feb 7.

PMID:
30733229
5.

Final Outcome of 223Ra-therapy and the Role of 18F-fluoride-PET in Response Evaluation in Metastatic Castration-resistant Prostate Cancer-A Single Institution Experience.

Kairemo K, Milton DR, Etchebehere E, Rohren EM, Macapinlac HA.

Curr Radiopharm. 2018;11(2):147-152. doi: 10.2174/1874471011666180629145030.

PMID:
29956640
6.

Hematologic Toxicity From Radium-223 Therapy for Bone Metastases in Castration-Resistant Prostate Cancer: Risk Factors and Practical Considerations.

Jacene H, Gomella L, Yu EY, Rohren EM.

Clin Genitourin Cancer. 2018 Aug;16(4):e919-e926. doi: 10.1016/j.clgc.2018.03.007. Epub 2018 Mar 23. Review.

7.

Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation.

Akhtari M, Milgrom SA, Pinnix CC, Reddy JP, Dong W, Smith GL, Mawlawi O, Abou Yehia Z, Gunther J, Osborne EM, Andraos TY, Wogan CF, Rohren E, Garg N, Chuang H, Khoury JD, Oki Y, Fanale M, Dabaja BS.

Blood. 2018 Jan 4;131(1):84-94. doi: 10.1182/blood-2017-04-773838. Epub 2017 Oct 16.

8.

Appropriate Use Criteria for 18F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease.

Jadvar H, Colletti PM, Delgado-Bolton R, Esposito G, Krause BJ, Iagaru AH, Nadel H, Quinn DI, Rohren E, Subramaniam RM, Zukotynski K, Kauffman J, Ahuja S, Griffeth L.

J Nucl Med. 2017 Dec;58(12):2026-2037. doi: 10.2967/jnumed.117.197988. Epub 2017 Oct 12. No abstract available.

9.

Utility of (18) F-FDG PET/CT and CECT in conjunction with serum CA 19-9 for detecting recurrent pancreatic adenocarcinoma.

Rayamajhi S, Balachandran A, Katz M, Reddy A, Rohren E, Bhosale P.

Abdom Radiol (NY). 2018 Feb;43(2):505-513. doi: 10.1007/s00261-017-1316-z.

PMID:
28900703
10.

Early-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: can residual pet-positive disease be cured with radiotherapy alone?

Milgrom SA, Pinnix CC, Chuang H, Oki Y, Akhtari M, Mawlawi O, Garg N, Gunther JR, Reddy JP, Smith GL, Rohren E, Hagemeister FB, Lee HJ, Fayad LE, Dong W, Osborne EM, Abou Yehia Z, Fanale M, Dabaja BS.

Br J Haematol. 2017 Nov;179(3):488-496. doi: 10.1111/bjh.14902. Epub 2017 Aug 18.

11.

Spectrum of Benign Bone Conditions on NaF-PET.

Rohren EM, Macapinlac HA.

Semin Nucl Med. 2017 Jul;47(4):392-396. doi: 10.1053/j.semnuclmed.2017.02.008. Epub 2017 Apr 18. Review.

PMID:
28583278
12.

ACR and SNMMI Joint Credentialing Statement for PET/MRI of the Body.

Subramaniam RM, Jadvar H, Colletti PM, Guimaraes A, Gullapali R, Iagaru AH, McConathy J, Meltzer CC, Nadel H, Noto RB, Packard AB, Rohren EM, Oates ME.

J Nucl Med. 2017 Jul;58(7):1174-1176. doi: 10.2967/jnumed.117.193524. Epub 2017 May 4. No abstract available.

13.

Chemotherapy Response Assessment by FDG-PET-CT in Early-stage Classical Hodgkin Lymphoma: Moving Beyond the Five-Point Deauville Score.

Milgrom SA, Dong W, Akhtari M, Smith GL, Pinnix CC, Mawlawi O, Rohren E, Garg N, Chuang H, Yehia ZA, Reddy JP, Gunther JR, Khoury JD, Suki T, Osborne EM, Oki Y, Fanale M, Dabaja BS.

Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):333-338. doi: 10.1016/j.ijrobp.2016.10.029. Epub 2016 Oct 22.

14.

Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers.

Takeuchi S, Rohren EM, Abdel-Wahab R, Xiao L, Morris JS, Macapinlac HA, Hassan MM, Kaseb AO.

Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):969-978. doi: 10.1007/s00259-016-3583-2. Epub 2016 Dec 12.

15.

Fat-Containing Hypermetabolic Masses on FDG PET/CT: A Spectrum of Benign and Malignant Conditions.

Rydzak C, Chauhan A, Gupta N, Chuang HH, Rohren EM, Bhosale PR.

AJR Am J Roentgenol. 2016 Nov;207(5):1095-1104. Epub 2016 Aug 4. Review.

PMID:
27490138
16.

IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma.

Lamhamedi-Cherradi SE, Menegaz BA, Ramamoorthy V, Vishwamitra D, Wang Y, Maywald RL, Buford AS, Fokt I, Skora S, Wang J, Naing A, Lazar AJ, Rohren EM, Daw NC, Subbiah V, Benjamin RS, Ratan R, Priebe W, Mikos AG, Amin HM, Ludwig JA.

J Natl Cancer Inst. 2016 Aug 30;108(12). pii: djw182. doi: 10.1093/jnci/djw182. Print 2016 Dec.

17.

State-of-the-Art Imaging and Staging of Plasma Cell Dyscrasias.

Amini B, Yellapragada S, Shah S, Rohren E, Vikram R.

Radiol Clin North Am. 2016 May;54(3):581-96. doi: 10.1016/j.rcl.2015.12.008. Epub 2016 Mar 21. Review.

PMID:
27153790
18.

Reply: Prediction vs. Prognostication and Guarantee-Time Bias: Steering Clear of the Pitfalls of Interpreting Observational Data.

Etchebehere EC, Fox P, Milton D, Macapinlac H, Rohren E.

J Nucl Med. 2016 Jun;57(6):991. doi: 10.2967/jnumed.116.172130. Epub 2016 Apr 14. No abstract available.

19.

State-of-the-art Imaging of Pancreatic Neuroendocrine Tumors.

Tamm EP, Bhosale P, Lee JH, Rohren EM.

Surg Oncol Clin N Am. 2016 Apr;25(2):375-400. doi: 10.1016/j.soc.2015.11.007. Review.

20.

Assessment of Sequential PET/MRI in Comparison With PET/CT of Pediatric Lymphoma: A Prospective Study.

Sher AC, Seghers V, Paldino MJ, Dodge C, Krishnamurthy R, Krishnamurthy R, Rohren EM.

AJR Am J Roentgenol. 2016 Mar;206(3):623-31. doi: 10.2214/AJR.15.15083.

PMID:
26901021
21.

Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT Predicts Bone Marrow Failure After 223Ra Therapy.

Etchebehere EC, Araujo JC, Milton DR, Erwin WD, Wendt RE 3rd, Swanston NM, Fox P, Macapinlac HA, Rohren EM.

Clin Nucl Med. 2016 Apr;41(4):268-73. doi: 10.1097/RLU.0000000000001118.

PMID:
26828141
22.

Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review.

Pinnix CC, Shah JJ, Chuang H, Costelloe CM, Medeiros LJ, Wogan CF, Reed V, Smith GL, Milgrom S, Patel K, Huo J, Turturro F, Romaguera J, Fayad L, Oki Y, Fanale MA, Westin J, Nastoupil L, Hagemeister FB, Rodriguez A, Qazilbash M, Shah N, Bashir Q, Ahmed S, Nieto Y, Hosing C, Rohren E, Dabaja B.

Clin Lymphoma Myeloma Leuk. 2016 Mar;16(3):122-8. doi: 10.1016/j.clml.2015.12.008. Epub 2015 Dec 22.

PMID:
26795083
23.

Comparison of Standardized Uptake Values in Normal Structures Between PET/CT and PET/MRI in a Tertiary Pediatric Hospital: A Prospective Study.

Lyons K, Seghers V, Sorensen JI, Zhang W, Paldino MJ, Krishnamurthy R, Rohren EM.

AJR Am J Roentgenol. 2015 Nov;205(5):1094-101. doi: 10.2214/AJR.15.14304.

PMID:
26496558
24.

Factors affecting (223)Ra therapy: clinical experience after 532 cycles from a single institution.

Etchebehere EC, Milton DR, Araujo JC, Swanston NM, Macapinlac HA, Rohren EM.

Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):8-20. doi: 10.1007/s00259-015-3185-4. Epub 2015 Sep 29.

PMID:
26416392
25.

Qualitative FDG PET Image Assessment Using Automated Three-Segment MR Attenuation Correction Versus CT Attenuation Correction in a Tertiary Pediatric Hospital: A Prospective Study.

Lyons K, Seghers V, Williams JL, Sorensen JI, Paldino MJ, Krishnamurthy R, Rohren EM.

AJR Am J Roentgenol. 2015 Sep;205(3):652-8. doi: 10.2214/AJR.14.14231.

PMID:
26295654
26.

Alpha Emitter Radium 223 in High-Risk Osteosarcoma: First Clinical Evidence of Response and Blood-Brain Barrier Penetration.

Subbiah V, Anderson P, Rohren E.

JAMA Oncol. 2015 May;1(2):253-5. doi: 10.1001/jamaoncol.2014.289. No abstract available.

PMID:
26181034
27.

Determination of Skeletal Tumor Burden on 18F-Fluoride PET/CT.

Rohren EM, Etchebehere EC, Araujo JC, Hobbs BP, Swanston NM, Everding M, Moody T, Macapinlac HA.

J Nucl Med. 2015 Oct;56(10):1507-12. doi: 10.2967/jnumed.115.156026. Epub 2015 Jul 1.

28.

Rectal Cancer, Version 2.2015.

Benson AB 3rd, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, Fuchs CS, Grem JL, Grothey A, Hochster HS, Hunt S, Kamel A, Kirilcuk N, Leong LA, Lin E, Messersmith WA, Mulcahy MF, Murphy JD, Nurkin S, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Freedman-Cass D.

J Natl Compr Canc Netw. 2015 Jun;13(6):719-28; quiz 728.

PMID:
26085388
29.

Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival.

Etchebehere EC, Araujo JC, Fox PS, Swanston NM, Macapinlac HA, Rohren EM.

J Nucl Med. 2015 Aug;56(8):1177-84. doi: 10.2967/jnumed.115.158626. Epub 2015 Jun 11.

30.

Proceedings of the Second NCI-SNMMI Workshop on Targeted Radionuclide Therapy.

Fahey F, Zukotynski K, Jadvar H, Capala J; organizing committee, contributors, and participants of the second NCI–SNMMI Workshop on Targeted Radionuclide Therapy.

J Nucl Med. 2015 Jul;56(7):1119-29. doi: 10.2967/jnumed.115.159038. Epub 2015 May 21. No abstract available.

31.

Non-Small Cell Lung Cancer, Version 6.2015.

Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Dilling TJ, Dobelbower MC, Govindan R, Grannis FW Jr, Horn L, Jahan TM, Komaki R, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild SE, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M; National comprehensive cancer network.

J Natl Compr Canc Netw. 2015 May;13(5):515-24.

PMID:
25964637
32.

PET/Computed Tomography and Patient Outcomes in Melanoma.

Rohren EM.

PET Clin. 2015 Apr;10(2):243-54. doi: 10.1016/j.cpet.2014.12.006. Epub 2015 Feb 21. Review.

PMID:
25829089
33.

American College of Radiology and Society of Nuclear Medicine and Molecular Imaging Joint Credentialing Statement for PET/MR Imaging: Brain.

Jadvar H, Subramaniam RM, Berman CG, Boada F, Colletti PM, Guimaraes AR, McConathy J, Meltzer CC, Noto RB, Packard AB, Rohren EM, Oates ME.

J Nucl Med. 2015 Apr;56(4):642-5. doi: 10.2967/jnumed.115.155218. Epub 2015 Mar 5. No abstract available.

34.

Non-small cell lung cancer, version 1.2015.

Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Dilling TJ, Govindan R, Grannis FW Jr, Horn L, Jahan TM, Komaki R, Kris MG, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild S, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M.

J Natl Compr Canc Netw. 2014 Dec;12(12):1738-61.

PMID:
25505215
35.

Combined Antiangiogenic and Mammalian Target of Rapamycin Inhibitor Targeted Therapy in Metaplastic Breast Cancer Harboring a PIK3CA Mutation.

Agarwal R, Koenig K, Rohren E, Subbiah V.

J Breast Cancer. 2014 Sep;17(3):287-90. doi: 10.4048/jbc.2014.17.3.287. Epub 2014 Sep 30.

36.

The acetabular fossa hot spot on 18F-FDG PET/CT: epidemiology, natural history, and proposed etiology.

Kubicki SL, Richardson ML, Martin T, Rohren E, Wei W, Amini B.

Skeletal Radiol. 2015 Jan;44(1):107-14. doi: 10.1007/s00256-014-2011-6. Epub 2014 Oct 7.

PMID:
25283982
37.

PET scanning: worth the cost in cancer? Not only worth the cost, but sometimes a cost-cutter!

Rohren EM.

Oncology (Williston Park). 2014 May;28(5):390, 392. No abstract available.

38.

Colon cancer, version 3.2014.

Benson AB 3rd, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, Messersmith W, Mulcahy MF, Murphy JD, Nurkin S, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Freedman-Cass DA; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2014 Jul;12(7):1028-59.

PMID:
24994923
39.

Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: samarium-153-EDTMP and radium-223.

Anderson PM, Subbiah V, Rohren E.

Adv Exp Med Biol. 2014;804:291-304. doi: 10.1007/978-3-319-04843-7_16. Review.

PMID:
24924181
40.

Prostate cancer, version 2.2014.

Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kane CJ, Kawachi MH, Kuettel M, Kuzel TM, Lee RJ, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M 3rd, Rohren E, Rosenfeld S, Schaeffer E, Small EJ, Sonpavde G, Srinivas S, Stein C, Strope SA, Tward J, Shead DA, Ho M; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2014 May;12(5):686-718.

PMID:
24812137
41.

Measuring the extent of total thyroidectomy for differentiated thyroid carcinoma using radioactive iodine imaging: relationship with serum thyroglobulin and clinical outcomes.

Holsinger FC, Ramaswamy U, Cabanillas ME, Lang J, Lin HY, Busaidy NL, Grubbs E, Rahim S, Sturgis EM, Lee JE, Weber RS, Clayman GL, Rohren EM.

JAMA Otolaryngol Head Neck Surg. 2014 May;140(5):410-5. doi: 10.1001/jamaoto.2014.264.

PMID:
24700275
42.

SNMMI comment on ASCO 2013 "Choosing wisely" recommendation on use of PET/CT in recurrent cancer surveillance.

Rohren EM, Dillehay GL, Jadvar H.

J Nucl Med. 2014 May;55(5):699-700. doi: 10.2967/jnumed.114.139683. Epub 2014 Mar 24. No abstract available.

43.

Is imaging the extremities with PEM feasible? A novel application for a high-resolution positron emission scanner.

Rahim S, Mawlawi O, Taylor S, Millican R, Swanston NM, Brown JE, Rohren EM.

Clin Imaging. 2014 May-Jun;38(3):307-13. doi: 10.1016/j.clinimag.2013.11.013. Epub 2013 Nov 27.

44.

What Is the Clinical Significance of FDG Unexpected Uptake in the Prostate in Patients Undergoing PET/CT for Other Malignancies?

Bhosale P, Balachandran A, Vikram R, Viswanathan C, Macapinlac H, Rohren E, Prativadi R.

Int J Mol Imaging. 2013;2013:476786. doi: 10.1155/2013/476786. Epub 2013 Dec 28.

45.

Impact of initial PET/CT staging in terms of clinical stage, management plan, and prognosis in 592 patients with non-small-cell lung cancer.

Takeuchi S, Khiewvan B, Fox PS, Swisher SG, Rohren EM, Bassett RL Jr, Macapinlac HA.

Eur J Nucl Med Mol Imaging. 2014 May;41(5):906-14. doi: 10.1007/s00259-013-2672-8. Epub 2014 Jan 18.

PMID:
24442598
46.

Correlation of PUV and SUV in the extremities while using PEM as a high-resolution positron emission scanner.

Rahim S, Mawlawi O, Fox P, Taylor S, Millican R, Swanston NM, Brown JE, Rohren EM.

Skeletal Radiol. 2014 Apr;43(4):453-8. doi: 10.1007/s00256-013-1795-0. Epub 2014 Jan 16.

47.

Prostate cancer, version 1.2014.

Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kawachi MH, Kuettel M, Lee RJ, Macvicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Richey S, Roach M 3rd, Rohren E, Rosenfeld S, Small EJ, Srinivas S, Stein C, Strope SA, Tward J, Walsh PC, Shead DA, Ho M; National comprehensive cancer network.

J Natl Compr Canc Netw. 2013 Dec 1;11(12):1471-9.

PMID:
24335682
48.

Joint statement by members of the NCCN Prostate Cancer Guidelines Panel.

Mohler JL; NCCN Prostate Cancer Panel.

J Natl Compr Canc Netw. 2013 Nov;11(11):1310-2. No abstract available.

PMID:
24225965
49.

(18)F-FDG PET/CT predicts survival in patients with inflammatory breast cancer undergoing neoadjuvant chemotherapy.

Carkaci S, Sherman CT, Ozkan E, Adrada BE, Wei W, Rohren EM, Mawlawi OR, Ueno NT, Buchholz TA, Yang WT.

Eur J Nucl Med Mol Imaging. 2013 Dec;40(12):1809-16. doi: 10.1007/s00259-013-2506-8. Epub 2013 Jul 23.

PMID:
23877633
50.

Non-small cell lung cancer, version 2.2013.

Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW Jr, Grant SC, Horn L, Jahan TM, Komaki R, Kong FM, Kris MG, Krug LM, Lackner RP, Lennes IT, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Shapiro TA, Swanson SJ, Tauer K, Wood DE, Yang SC, Gregory K, Hughes M; National comprehensive cancer network.

J Natl Compr Canc Netw. 2013 Jun 1;11(6):645-53; quiz 653.

PMID:
23744864

Supplemental Content

Loading ...
Support Center